Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

As we age, we experience changes in our nighttime sleep and daytime wakefulness.
Individuals afflicted with Alzheimer's disease (AD) can develop sleep problems even before …

We previously found that Mertk and its ligand Gas6, astrocytic genes involved in
phagocytosis, are upregulated after acute sleep deprivation. These results suggested that …

Microglia are emerging as key players in neurodegenerative diseases, such as Alzheimer's
disease (AD). Thus far, microglia have rather been known as modulator of …

Polysomnography (PSG) studies of sleep changes in Alzheimer's disease (AD) have
reported but not fully established the relationship between sleep disturbances and AD. To …

None of the proposed mechanisms of Alzheimer's disease (AD) fully explains the distribution
patterns of the neuropathological changes at the cellular and regional levels, and their …

Here we critically review studies that used electroencephalography (EEG) or event-related
potential (ERP) indices as a biomarker of Alzheimer's disease. In the first part we overview …

Objective: Sleep disturbance is common in dementia, although it is unclear whether
differences in sleep architecture precede dementia onset. We examined the associations …

During wakefulness, extracellular levels of metabolites in the brain increase. These include
amyloid beta (Aβ), which contributes to the pathogenesis of Alzheimer's disease (AD) …

Amyloid-β (Aβ) plaques are a key histopathological hallmark of Alzheimer's disease (AD),
and soluble Aβ species are believed to play an important role in the clinical development of …